NEW YORK, April 11, 2014 /PRNewswire/ -- Navidea Pharmaceuticals, Inc. (NYSEMKT: NAVB), is a biopharmaceutical company that is focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Its core product, Lymphoseek, a small-molecule radiopharmaceutical used in lymphatic mapping procedures, helps physician identify and target the lymph nodes that drain from a primary tumor that contain cancer cells.
The U.S. Food and Drug Administration, in March 2013 approved the use of Lymphoseek in lymphatic mapping to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma. Subsequently, the company, and its partner, Cardinal Health Inc.'s Nuclear Pharmacy Services division, launched Lymphoseek in the United States in May 2013.
Navidea expects to receive approval for using Lymphoseek in additional indications in U.S, including head and neck cancer, later in the year. The company also anticipates that it will obtain approval sell the product in Europe in 2014 and, then launch it in the major European markets in 2015.
These potential positive regulatory milestones do not alter the basic belief that Lymphoseek is a "niche product" whose potential is more than limited than what is being projected by the sell-side analyst community. The analyst report will provide further information with respect to the anticipated potential of Lymphoseek as well as discuss the key attribute of the product, provide an overview of the company, and review financial results for fiscal 2013. There is no cost required to view this report:http://bit.ly/NAVB-CFA-Report copy and paste to browser may be required Disclaimer: The information contained herein is not intended to be investment advice and does not constitute any form of invitation or inducement by Paul Bienstock, CFA and Money by Maggi to engage in investment activity. Neither the information nor any opinion expressed constitutes a solicitation for the purchase or sale of any security. Securities, financial instruments, strategies, or commentary mentioned herein may not be suitable for all investors and this material is not intended for any specific investor and does not take into account an investor's particular investment objectives, financial situations or needs. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only current as of the stated date of their issue. Prices, values, or income from any securities or investments mentioned in this report may fluctuate, and an investor may, upon selling an investment lose a portion of, or the entire principal amount invested. Past performance is no guarantee of future results. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice. This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.